Ask AI
HER2 Targeted ADCs AE Management

CME

HER2-Targeted ADCs in Genitourinary, Gastrointestinal, and Gynecological Malignancies: Safety and Adverse Event Management

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: September 03, 2025

Expiration: March 02, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

A 62-year-old patient receiving trastuzumab deruxtecan (T-DXd) for gastric adenocarcinoma cancer reports a new dry cough and mild dyspnea. Imaging shows bilateral ground-glass opacities, and interstitial lung disease (ILD)/pneumonitis is confirmed. What would you recommend to manage this adverse event (AE)?

2.

Which of the following statements best describes the clinical significance of ILD associated with T-DXd?

3.

A 64-year-old patient with HER2-positive urothelial carcinoma is receiving disitamab vedotin (DV) at 2.0 mg/kg every 2 weeks on a clinical trial. After cycle 5, the patient develops new numbness and tingling in her fingertips. Exam confirms grade 2 peripheral sensory neuropathy. In addition to supportive care, which of the following is the most appropriate next step?